Igor M. Belyakov1, Zdenek Hel2, Brian Kelsall3, Vladimir A. Kuznetsov4, Jeffrey D. Ahlers1, Janos Nacsa2, David I. Watkins5, Todd M. Allen5, Alessandro Sette6, John Altman7, Ruth Woodward8, Phillip D. Markham8, John D. Clements9, Genoveffa Franchini2, Warren Strober3
& Jay A. Berzofsky11
Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, Bethesda, Maryland, USA
2
Animal Model and Retroviral Vaccines Section, Basic Research Laboratory, National Cancer Institute, Bethesda, Maryland, USA
3
Mucosal Immunity Section, Laboratory Of Clinical Investigation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
4
Section of Medical Biophysics, Laboratory of Integrative and Medical Biophysics, National Institute of Child Health and Human Development, Bethesda, Maryland, USA
5
Wisconsin Regional Primate Research Center, Madison, Wisconsin, USA
6
Epimmune, San Diego, California, USA
7
Emory University Vaccine Center at Yerkes, Atlanta, Georgia, USA
8
Advanced BioScience Laboratories, Kensington, Maryland, USA
9
Department of Microbiology and Immunology, Program in Molecular Pathogenesis and Immunity, Tulane University School of Medicine, New Orleans, Louisiana, USA
Correspondence should be addressed to Jay A. Berzofsky berzofsk@helix.nih.gov or Igor M. Belyakov belyakov@box-b.nih.gov
